Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
acenocoumarol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Acenocoumarol + Vemurafenib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| acenocoumarol | DRUG | 4 mg single oral doses on Days 1 and 23 |
| vemurafenib | DRUG | 960 mg orally bid, 20 days (Days 4-23) |
Inclusion Criteria: * Adult patients, 18-70 years of age * Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who have no acceptable standard treatment options * Eastern Cooperative Oncology ...
Acenocoumarol is a small molecule drug candidate being developed by Roche Holding AG (ticker RHHBY). It is being studied in oncology, specifically in malignant melanoma and other neoplasms. It is an investigational agent in Phase 1 development and has not been approved for these cancer indications.
Acenocoumarol targets VKORC1 and acts as an inhibitor of this target. VKORC1 is the enzyme targeted by vitamin K antagonist anticoagulants. In this development program, the drug is being evaluated in patients with malignant melanoma and other neoplasms.
Acenocoumarol is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor associated with the clinical development of this small molecule agent in oncology.
Acenocoumarol is in Phase 1 clinical development for malignant melanoma and neoplasms. It is an investigational drug and is not approved for these cancer indications. The Phase 1 program includes one completed trial with no active trials currently listed.
Acenocoumarol has been studied in trial NCT01851824, titled A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy. This Phase 1 trial is completed, enrolled 9 patients, and was conducted in Australia, Germany, Greece, Hungary, the Netherlands, New Zealand, Portugal, Serbia, and Spain.